Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of atezolizumab and bevacizumab in patients with rare solid tumors, including pancreatic cancer.
General Information
NCT#: NCT03074513
Study ID: 2016-0861
Trial Phase: Phase II
Trial Sponsor: Genentech, M.D. Anderson Cancer Center
Therapies Used in This Trial: Bevacizumab, Atezolizumab